AIM: The objective of this study was to investigate whether the pharmacokinetics of orally administered levofloxacin show 24 h variation. Levofloxacin was used as a model compound for solubility and permeability independent absorption and passive renal elimination. METHODS: In this single centre, crossover, open label study, 12 healthy subjects received an oral dose of 1000 mg levofloxacin at six different time points equally divided over the 24 h period. Population pharmacokinetic modelling was used to identify potential 24 h variation in the pharmacokinetic parameters of this drug. RESULTS: The pharmacokinetics of levofloxacin could be described by a one compartment model with first order clearance and a transit compartment to describe drug absorption. The fit of the model was significantly improved when the absorption rate constant was described as a cosine function with a fixed period of 24 h, a relative amplitude of 47% and a peak around 08.00 h in the morning. Despite this variation in absorption rate constant, simulations of a once daily dosing regimen showed that tmax , Cmax and the area under the curve at steady-state were not affected by the time of drug administration. CONCLUSION: The finding that the absorption rate constant showed considerable 24 h variation may be relevant for drugs with similar physicochemical properties as levofloxacin that have a narrower therapeutic index. Levofloxacin, however, can be dosed without taking into account the time of day, at least in terms of its pharmacokinetics.
RCT Entities:
AIM: The objective of this study was to investigate whether the pharmacokinetics of orally administered levofloxacin show 24 h variation. Levofloxacin was used as a model compound for solubility and permeability independent absorption and passive renal elimination. METHODS: In this single centre, crossover, open label study, 12 healthy subjects received an oral dose of 1000 mg levofloxacin at six different time points equally divided over the 24 h period. Population pharmacokinetic modelling was used to identify potential 24 h variation in the pharmacokinetic parameters of this drug. RESULTS: The pharmacokinetics of levofloxacin could be described by a one compartment model with first order clearance and a transit compartment to describe drug absorption. The fit of the model was significantly improved when the absorption rate constant was described as a cosine function with a fixed period of 24 h, a relative amplitude of 47% and a peak around 08.00 h in the morning. Despite this variation in absorption rate constant, simulations of a once daily dosing regimen showed that tmax , Cmax and the area under the curve at steady-state were not affected by the time of drug administration. CONCLUSION: The finding that the absorption rate constant showed considerable 24 h variation may be relevant for drugs with similar physicochemical properties as levofloxacin that have a narrower therapeutic index. Levofloxacin, however, can be dosed without taking into account the time of day, at least in terms of its pharmacokinetics.
Authors: Kelly A Sprandel; Christopher A Schriever; Susan L Pendland; John P Quinn; Mark H Gotfried; Suzanne Hackett; Mary Beth Graham; Larry H Danziger; Keith A Rodvold Journal: Antimicrob Agents Chemother Date: 2004-12 Impact factor: 5.191
Authors: S C Chien; M C Rogge; L G Gisclon; C Curtin; F Wong; J Natarajan; R R Williams; C L Fowler; W K Cheung; A T Chow Journal: Antimicrob Agents Chemother Date: 1997-10 Impact factor: 5.191
Authors: F Fauvelle; P Perrin; L Belfayol; M Boukari; P Cherrier; A M Bosio; M Tod; J M Coulaud; O Petitjean Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191
Authors: Laura Kervezee; Jasper Stevens; Willem Birkhoff; Ingrid M C Kamerling; Theo de Boer; Melloney Dröge; Johanna H Meijer; Jacobus Burggraaf Journal: Br J Clin Pharmacol Date: 2015-11-25 Impact factor: 4.335
Authors: Simone H J van den Elsen; Marieke G G Sturkenboom; Natasha Van't Boveneind-Vrubleuskaya; Alena Skrahina; Tjip S van der Werf; Scott K Heysell; Stellah Mpagama; Giovanni B Migliori; Charles A Peloquin; Daan J Touw; Jan-Willem C Alffenaar Journal: Antimicrob Agents Chemother Date: 2018-11-26 Impact factor: 5.191
Authors: L Kervezee; V Gotta; J Stevens; W Birkhoff; Imc Kamerling; M Danhof; J H Meijer; J Burggraaf Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-08-01